Multicentric Database for KRAS Mutant Pancreatic Cancer

Sponsor
Fudan University
Study ID
NCT07557849
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
N/A - N/A
Healthy Volunteers
Not accepted

Study Details

Construction and Maintenance of a Precision Subtyping-Based Clinical Cohort for Targeted Therapy in KRAS-Mutant Pancreatic Cancer

Key Dates

First listed
Apr 30, 2026
Start date
May 22, 2026
Status verified
Apr 2026
Primary completion
Apr 30, 2028
Completion
Apr 30, 2029

Study Design

Enrollment
1,000 participants (estimated)

Arms

  • Arm: Pancreatic cancer with KRAS mutation
    Patients with pancreatic cancer with KRAS mutation who received KRAS targeted therapy

Primary Outcome Measure

Overall survival [ Time Frame: 12 months ]

Central Contacts

Find similar trials

Nationwide
Pancreatic cancer trialsOncology trialsGI oncology trials

Related Studies